In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, April 2014

Executive Summary

This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.

You may also be interested in...



EBS Technologies GMBH

EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.

Xeltis AG

Rather than relying on an animal or cadaver implant to repair severe congenital heart malformations, Xeltis AG has developed a synthetic and biodegradable replacement pulmonary valve, designed to stimulate and guide the body’s natural healing response. The company’s technology, which has opened up an entirely new therapeutic category called endogenous tissue growth, is designed to provide a single intervention that can last for a lifetime.

CoolCore Biomedical Technologies LLC

Similar to holding a lighted match near a thermostat to induce a lower room temperature, CoolCore Biomedical Technologies LLC’s technology cools the body by tricking it into thinking it is hotter than it actually is. According to its founders, SmartCool is the only totally noninvasive effective cooling technology designed to prevent or limit reperfusion injury (brain and tissue damage) within the critical initial time frame following an ischemic event such as sudden cardiac arrest, stroke, or traumatic brain injury.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel